Cargando…
Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine Methyltransferase
SMYD3 is a multifunctional epigenetic enzyme with lysine methyltransferase activity and various interaction partners. It is implicated in the pathophysiology of cancers but with an unclear mechanism. To discover tool compounds for clarifying its biochemistry and potential as a therapeutic target, a...
Autores principales: | Talibov, Vladimir O., Fabini, Edoardo, FitzGerald, Edward A., Tedesco, Daniele, Cederfeldt, Daniela, Talu, Martin J., Rachman, Moira M., Mihalic, Filip, Manoni, Elisabetta, Naldi, Marina, Sanese, Paola, Forte, Giovanna, Lepore Signorile, Martina, Barril, Xavier, Simone, Cristiano, Bartolini, Manuela, Dobritzsch, Doreen, Del Rio, Alberto, Danielson, U. Helena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248052/ https://www.ncbi.nlm.nih.gov/pubmed/33400854 http://dx.doi.org/10.1002/cbic.202000736 |
Ejemplares similares
-
Identifying novel SMYD3 interactors on the trail of cancer hallmarks
por: Fasano, Candida, et al.
Publicado: (2022) -
Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality
por: Sanese, Paola, et al.
Publicado: (2020) -
SMYD3 Modulates the HGF/MET Signaling Pathway in Gastric Cancer
por: De Marco, Katia, et al.
Publicado: (2023) -
The chromatin remodeling factors EP300 and TRRAP are novel SMYD3 interactors involved in the emerging ‘nonmutational epigenetic reprogramming’ cancer hallmark
por: Fasano, Candida, et al.
Publicado: (2023) -
SMYD3 Modulates AMPK-mTOR Signaling Balance in Cancer Cell Response to DNA Damage
por: Lepore Signorile, Martina, et al.
Publicado: (2023)